Literature DB >> 12879632

[Non-lipid effects of statins: myth or fact?].

Eleonora Urbauer1, Christian Joukhadar.   

Abstract

Hydroxy-methylglutaryl coenzyme A reductase-inhibitors (HMG-CoA [statins]) are currently the most effective method to pharmacologically decrease total plasma cholesterol levels. A number of multicenter studies have demonstrated, that statins administered for several years lead to a significant reduction of cardiovascular events and mortality compared with placebo. Apart from the well known LDL- and cholesterol lowering effect, statins have been postulated to exert beneficial effects on mortality due to so called 'non-lipid effects'. There is circumstantial evidence from a number of experimental studies that statins can improve endothelial function, exert anti-inflammatory and anti-oxidative effects, stabilize arteriosclerotic plaque and inhibit proliferation and activation of smooth muscle cells. However, the clinical implications of these beneficial 'non-lipid effects' are unclear, but appear to exert only a minor role in comparison to the lowering effect of statins on total plasma cholesterol levels.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12879632     DOI: 10.1046/j.1563-258x.2003.03028.x

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  95 in total

1.  Endothelial dysfunction in atherosclerosis.

Authors:  A D Callow
Journal:  Vascul Pharmacol       Date:  2002-05       Impact factor: 5.773

2.  C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis.

Authors:  T P Zwaka; V Hombach; J Torzewski
Journal:  Circulation       Date:  2001-03-06       Impact factor: 29.690

3.  Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month.

Authors:  G O'Driscoll; D Green; R R Taylor
Journal:  Circulation       Date:  1997-03-04       Impact factor: 29.690

4.  Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins.

Authors:  T B Rajavashisth; A Andalibi; M C Territo; J A Berliner; M Navab; A M Fogelman; A J Lusis
Journal:  Nature       Date:  1990-03-15       Impact factor: 49.962

5.  Inhibition of growth factor signaling pathways by lovastatin.

Authors:  T S Vincent; E Wülfert; E Merler
Journal:  Biochem Biophys Res Commun       Date:  1991-11-14       Impact factor: 3.575

6.  Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolaemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors.

Authors:  H A Kleinveld; P N Demacker; A F De Haan; A F Stalenhoef
Journal:  Eur J Clin Invest       Date:  1993-05       Impact factor: 4.686

7.  Differential effects of monoterpenes and lovastatin on RAS processing.

Authors:  R J Hohl; K Lewis
Journal:  J Biol Chem       Date:  1995-07-21       Impact factor: 5.157

Review 8.  Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation.

Authors:  C J Marshall
Journal:  Cell       Date:  1995-01-27       Impact factor: 41.582

9.  The effect of pravastatin on acute rejection after kidney transplantation--a pilot study.

Authors:  S Katznelson; A H Wilkinson; J A Kobashigawa; X M Wang; D Chia; M Ozawa; H P Zhong; M Hirata; A H Cohen; P I Teraski
Journal:  Transplantation       Date:  1996-05-27       Impact factor: 4.939

10.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.